# JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

> **NCT06244862** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 42 (estimated)

## Conditions studied

- Hemophagocytic Syndromes

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT06244862
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2025-08-08
- **Final completion:** 2026-02-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244862, "JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06244862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*